A week ago, BioAge Labs, Inc. (NASDAQ:BIOA) came out with a strong set of first-quarter numbers that could potentially lead to a re-rate of the stock. Revenue crushed expectations at US$2.8m, beating expectations by 156%. BioAge Labs reported a statutory loss of US$0.52 per share, which - although not amazing - was much smaller than the analysts predicted. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on BioAge Labs after the latest results.

Taking into account the latest results, the consensus forecast from BioAge Labs' seven analysts is for revenues of US$85.2m in 2026. This reflects a sizeable 726% improvement in revenue compared to the last 12 months. Losses are predicted to fall substantially, shrinking 82% to US$0.37. Before this earnings announcement, the analysts had been modelling revenues of US$72.4m and losses of US$2.74 per share in 2026. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.

It will come as no surprise to learn thatthe analysts have increased their price target for BioAge Labs 33% to US$53.33on the back of these upgrades. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values BioAge Labs at US$73.00 per share, while the most bearish prices it at US$23.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The analysts are definitely expecting BioAge Labs' growth to accelerate, with the forecast 16x annualised growth to the end of 2026 ranking favourably alongside historical growth of 611% per annum over the past year. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 8.7% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that BioAge Labs is expected to grow much faster than its industry.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple BioAge Labs analysts - going out to 2028, and you can see them free on our platform here.

You still need to take note of risks, for example - BioAge Labs has 3 warning signs (and 1 which is a bit concerning) we think you should know about.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.